Spruce Biosciences reported a net loss of $16.2 million, or $(6.68) per share, for the second quarter ended June 30, 2026, with cash and cash equivalents rising to $96.3 million from $48.9 million at year-end 2025. The company announced a combined $5.5 million strategic investment from Cure Sanfilippo Foundation and the National MPS Society to fund an Expanded Access Program for its lead candidate TA-ERT. Management anticipates submitting a Biologics License Application (BLA) for TA-ERT in the fourth quarter of 2026, with the TrAnsform confirmatory study also expected to initiate then. Additionally, Spruce appointed Adrian Quartel as Chief Medical Officer and Jessica Cohen Pfeffer as Vice President of Clinical Development to support regulatory and commercial readiness. The company operates in the biopharmaceutical industry, developing novel therapies for neurological disorders.

Spruce Biosciences, Inc. appointed Adrian Quartel, M.D., FFPM, as its new Chief Medical Officer, replacing Dr. Kirk Ways, who will remain on the Board of Directors. Dr. Quartel has extensive experience in rare disease therapies and rare disease portfolio management. Spruce Biosciences, Inc. is a biotechnology company focused on developing treatments for rare diseases.